Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05312879 · ClinicalTrials.gov registry record · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
A Phase 2 study of Proteinuric Kidney Disease, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 466
- Enrollment target
- 20
- Study locations
NCT05312879: Recruiting Phase 2 study of Proteinuric Kidney Disease, sponsored by Vertex Pharmaceuticals Incorporated.
NCT05312879 is a Phase 2 study of Proteinuric Kidney Disease that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 466 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (250% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05312879, a Phase 2 study of Proteinuric Kidney Disease, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 466 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-147
Study Locations (20)
Alabama
- Alabama Kidney Research - Alabaster
- EmVenio Research - Mobile Unit - Birmingham - Birmingham
- Cardiology, P.C. - Birmingham
- Children's Hospital of Alabama - Birmingham
- The Kirklin Clinic - Nephrology - Birmingham
- Nephrology Associates - Fairhope
- Heart Center Research LLC - Huntsville
- Nephrology Consultants, LLC - Huntsville
- Renal Associates of Alabama, LLC - Montgomery
California
- The Medical Research Group - Saint Agnes Medical Center - Fresno
- Amicis Research Center - Balboa - Granada Hills
- Kidney Care Center of North Valley - Granada Hills
- Eastside Clinical Research Associates - Los Angeles
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
Arizona
- Arizona Kidney Disease and Hypertension Center - Banner Desert Office - Mesa
- Arizona Kidney Disease and Hypertension Center - Thomas Office - Phoenix
- Phoenix Children's Hospital, Inc. - Nephrology - Phoenix
Arkansas
- CHI St. Vincent Heart Clinic Arkansas- Cardiology and Medicine Clinic - Little Rock - Little Rock
- UAMS Medical Center - Pulmonology - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
What NCT05312879 shows while recruiting
NCT05312879 is an interventional study that assigns participants to a tested intervention. The registered 466 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (250% higher).
The record links to 1 condition, with Proteinuric Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05312879 names 20 study sites across 4 states, led by Alabama, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05312879 about?
NCT05312879 is a clinical study titled "Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease". The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
What is the current status of trial NCT05312879?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 466 participants. The study started on 2022-03-30. Estimated completion is 2026-06-30.
What conditions does trial NCT05312879 study?
This clinical trial studies the following conditions: Proteinuric Kidney Disease.
What interventions are being tested in trial NCT05312879?
The interventions under investigation include: Placebo (DRUG), VX-147 (DRUG).
Who is sponsoring clinical trial NCT05312879?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05312879 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proteinuric Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05312879's enrollment target sits among peer trials
466 80th of 2000 higher than 1,921 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06917404 · 466 participants · Phase 3
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
- NCT07055165 · 466 participants · NA
Connect2Care: Prostate Cancer Education and Screenings for African American Men
- NCT07214779 · 466 participants · Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- NCT06456554 · 467 participants · NA
Acellular Dermal Matrix Investigation in Breast Reconstruction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI